Skip to main content
All lobbying filings

MERCK & CO, INC.

Lobbying for MERCK & CO INC

 Filing 3rd Quarter - Report
3rd Quarter (July 1 - Sep 30) 2025 · New Jersey · House · Senate · $1,520,000.00 expenses · posted Oct 20, 2025

Official filing document

 Bills named in this filing 4
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • S 1339
    Stop CCP Money Laundering Act of 2025
  • S 2076
    HCBS Relief Act of 2025
  • S 1163
    Rural Veterinary Workforce Act
 Lobbying activity 4
Health Issues

H.R. 1, One Big Beautiful Bill, issues related to health care S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues; Cost and value of medicines; Vaccine issues; Package inserts and e-labeling Package inserts, labeling issues, and e-labeling authorization legislation; Pharmaceutical supply channel issues; Drug shortages issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2026 Budget and Appropriations Legislation; Budget reconciliation drug pricing provisions; Commerce Justice, Science, and related agencies appropriations legislation for 2026; Interior, Environment, and related agencies appropriations legislation for 2026; Intellectual property protection and trade issues; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; General pharmaceutical issues; Vaccine Injury Compensation Program (VICP); Pharmacy Benefit Manager (PBM) policy issues; Pharmacy Benefit Manager reforms; Food and Drug Administration issues; Public Health Issues; Most Favored Nation (MFN) drug pricing.

Medicare/Medicaid

H.R. 1, One Big Beautiful Bill, issues related to health care Issues relating to, Medicare; Medicare Part B and D drug pricing issues; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug pricing; Medicaid drug rebate program Cost and value of medicines: Drug pricing and reimbursement issues; FY-2026 Budget and Appropriations Legislation; Medicaid drug rebate program (MDRP).

Taxation/Internal Revenue Code

Issues relating to, Tax reform and tax policy, generally; Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes.

Animals

Issues relating to, S. 1163, Rural Veterinary Workforce Act Agriculture; Animal Health Technology; Animal Health Policy Issues; Animal Drug User Fee Act (ADUFA) & Funding for Electronic Animal Traceability; Rural development; Administration and related agencies appropriations bill, FY-26.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem